8-K: Artelo Biosciences Secures Flexible $6.5 Million At-The-Market Equity Program

Artelo Biosciences, Inc. has established an At-The-Market Offering Agreement to sell up to $6.5 million of its common stock, providing a flexible mechanism for future capital raises.

Summary

• Artelo Biosciences, Inc. entered into an At-The-Market Offering Agreement (the "Sales Agreement") with R.F. Lafferty & Co., Inc. (the "Manager") on July 18, 2025.
• The agreement establishes an at-the-market equity program allowing the Company to sell up to an aggregate of $6,500,000 of its common stock, par value $0.001 per share.
• Sales will be conducted through the Manager as a sales agent, primarily on The Nasdaq Capital Market or any other existing trading market, at prevailing market prices, or through a market maker.
• The Company will pay the Manager a commission rate of 2.0% of the gross sales price per share of common stock sold.
• The Company has no obligation to sell any shares and may suspend the offering at any time upon notice to the Manager.
• The ATM Offering will terminate upon the earlier of the sale of all shares subject to the Sales Agreement or termination of the Sales Agreement by either party with five days' prior notice.
• A prospectus supplement relating to this ATM Offering was filed with the SEC on July 18, 2025, under a previously effective Form S-3 registration statement from July 14, 2023, which registered $75,000,000 of common stock for potential at-the-market offerings.

Sentiment

Score: 7

Explanation: The establishment of an ATM facility is generally a positive step for a company as it provides a flexible and efficient means to raise capital, which is crucial for funding operations, research, or growth. While it introduces potential for dilution, the ability to access capital on demand is a net positive for financial flexibility and stability.

Positives

• Provides Artelo Biosciences with a flexible and efficient mechanism to raise capital as needed, without the fixed costs and lead time of traditional underwritten offerings.
• Allows the Company to access public markets for funding opportunistically, potentially minimizing price impact compared to large block sales.
• The ability to suspend sales offers the Company control over the timing of capital raises based on market conditions and funding requirements.

Negatives

• Potential for dilution of existing shareholders as new shares are issued under the program.
• The timing and pricing of share sales are subject to market conditions, which could impact the total amount of capital raised or the average price per share.
• There is no guaranteed capital raise from this agreement, as the Company has no obligation to sell any shares.

Risks

• Market price fluctuations could negatively impact the proceeds received from share sales, as shares are sold at prevailing market prices.
• The Company's ability to raise the full $6,500,000 is dependent on market demand and the Company's stock performance.
• Dilution of existing shareholders' ownership percentage and earnings per share due to the issuance of new common stock.
• The Manager is not obligated to purchase shares on a principal basis, except as specifically agreed in a separate Terms Agreement, meaning sales are dependent on market demand.
• The offering can be suspended or terminated by either the Company or the Manager, which could affect the Company's ability to raise planned capital.

Future Outlook

The At-The-Market Offering Agreement provides Artelo Biosciences with a flexible financing tool to raise capital as needed, supporting future operations and strategic initiatives. The Company has no obligation to sell shares, allowing it to manage capital raises based on market conditions and funding requirements.

Industry Context

At-The-Market (ATM) offerings are a common and flexible capital-raising mechanism for publicly traded companies, particularly in sectors like biotechnology or pharmaceuticals (implied by 'Biosciences' in the company name), where ongoing research and development often require continuous funding. This type of offering allows companies to tap into equity markets opportunistically, minimizing the upfront costs and market disruption associated with traditional underwritten offerings. It is a standard practice for companies seeking to maintain liquidity and fund operations or growth initiatives.

Comparison to Industry Standards

• The 2.0% commission rate for the Manager is within the typical range for ATM offerings, which generally vary from 1.0% to 3.0% depending on the size of the offering and the company's market capitalization.
• The use of an ATM facility is a standard practice for small to mid-cap companies, especially those in growth-oriented sectors, to efficiently access capital without the significant lead time and fixed costs of a firm commitment offering.
• The structure, including the ability to suspend sales and the lack of obligation to sell, aligns with industry best practices for maximizing flexibility for the issuer.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock. However, the ability to raise capital can support long-term growth and stability, potentially benefiting shareholders.
• Company Operations: Provides access to capital to fund ongoing operations, research and development, or other strategic initiatives, ensuring financial flexibility.
• Management: Gains flexibility in managing the Company's capital structure and funding needs, allowing for opportunistic capital raises.

Next Steps

• The Company may issue sales notices to the Manager to sell shares under the ATM program.
• The Manager will use commercially reasonable efforts to sell shares as instructed by the Company.
• Settlement for sales will typically occur on the first trading day following the date of sale.
• The Company will disclose the number of shares sold, net proceeds, and compensation in its Annual and Quarterly Reports, and potentially more frequently if required by SEC policy.

Key Dates

Keywords

Artelo Biosciences, ARTL, At-The-Market Offering, ATM, Equity Program, Capital Raise, Common Stock, SEC Filing, Form 8-K, R.F. Lafferty & Co., Dilution, Nasdaq Capital Market